Brief: Paion Assigns Chinese Remimazolam Patents And Sells Future Royalties To Humanwell Healthcare Group
07/01/2022 13:06
Jan 7 (Reuters) - PAION AG PA8G.DE :
* ASSIGNS CHINESE REMIMAZOLAM PATENTS AND SELLS RELATED
FUTURE
ROYALTIES FOR EUR 20.5 MILLION TO HUMANWELL HEALTHCARE GROUP
* A SPECIALTY PHARMA COMPANY (FSE:PA8), AND WUHAN HUMANWELL
INNOVATIVE DRUG RESEARCH AND DEVELOPMENT CENTER LIMITED COMPANY,
A WHOLLY-OWNED SUBSIDIARY OF HUMANWELL HEALTHCARE, ENTERED INTO
A PATENT ASSIGNMENT AGREEMENT
Source text for Eikon: ID:nEQ4gMXzJa
Further company coverage: PA8G.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on PAION AG
See all newsBrief: Paion AG To Issue Approx 4.8 Mln Shares In Capital Increase With Subscription Rights
Brief: Paion AG Reports Developments On Commercial Activities In Europe
Brief: Paion Q1 EBITDA Up At EUR 15 Mln
Brief: Paion Grants Exclusive License To Cristália For Development And Commercialization Of Remimazolam In Latin America
Brief: Paion Announces Sebastian Werner As New CFO, Effective 1 June 2022